Independent, up-to-date news and information for multiple myeloma patients and their families.
Headline » Opinion
Over the course of 2011, multiple myeloma patients and caregivers graciously shared their personal experiences with myeloma in columns they wrote for The Beacon. Some have taken a chronological approach to describing the events leading up to their diagnosis, through their treatment, and to where they are currently. Others have written about their struggles with side effects, relapsing, and dealing with the disease emotionally. Some have provided tips based on their own experiences, and others have told their story with humor and a positive outlook. As a service to its readers, The Myeloma Beacon has compiled a list of the columnist articles Beacon readers found most interesting during 2011. If you sometimes feel like you are battling this disease alone, please read these columns. It helps to know others have had similar experiences. Also, please join all of us here at The Beacon in expressing our sincere appreciation to these columnists for taking the time, and for being willing, to share their personal stories with… Read the full story » |
Featured |
The Myeloma Beacon is brought to you in part by:
Celgene announced this morning that it plans to submit an application for the approval of pomalidomide for relapsed and refractory multiple myeloma to the U.S. Food and Drug Administration (FDA) during the first quarter of 2012.
In addition, the company said that it plans to submit a similar application to the European Medicines Agency (EMA) during the first half of this year.
The updated submission timeline means that pomalidomide could be approved for use in the United States and in Europe by the end of this year.
Celgene’s announcement was made…
After my multiple myeloma diagnosis two years ago, I started my bi-weekly chemotherapy regimen. I quickly developed a routine.
Tuesdays and Fridays, I would take a ten-minute subway ride from our home in lower Manhattan to Greenwich Village, spend an hour at the clinic getting my “infusion,” and then stop off at one of the many great food stores at the cavernous Chelsea Market, a block from the clinic.
I’d then hop back on the subway and get to work, usually by 11 a.m. I was upbeat. This seemed bearable.…
Earlier this week, the U.S. Food and Drug Administration approved subcutaneous administration of Velcade (see related Beacon news). Previously, intravenous administration was the only approved method.
More details are provided in this article to answer multiple myeloma patients’ questions about the FDA decision.
What exactly did the FDA approve?
The FDA approved a supplemental new drug application for Velcade (bortezomib), which is an application to make changes to an already approved product. Specifically, the FDA approved updated prescribing information that now says Velcade can be administered by intravenous…
The Chinese New Year arrives this week. A culture with so much impact on the world can hardly be ignored. “The Year of the Dragon” suggests an energetic shift on the planet. The protective and powerful dragon symbolizes wisdom and prosperity. Generous, benevolent, and lucky, the dragon can transform into any type of creature and overcome all challenges.
Taming and transforming the multiple myeloma beast takes more than a dragon, but inspiration helps. Sometimes the dreams that occur during sleep can lead to new meaning and ways to see how…
Millennium: The Takeda Oncology Company announced today that the U.S Food and Drug Administration has approved subcutaneous administration of Velcade for the treatment of multiple myeloma and relapsed mantle cell lymphoma.
Velcade (bortezomib), which is marketed by Millennium and its parent company Takeda Pharmaceutical Company Limited (TSE:4502), is currently approved to be administered intravenously (infused into a vein).
The FDA decision to approve the subcutaneous administration of Velcade (injection into fat just below the skin, often abbreviated as subcu or subQ) was based on results of a Phase 3 study…
